ArticleInternational journal of nanomedicine2026
A Graphene Oxide-Doped CuMOF Nanoplatform Enhances Chemodynamic Therapy and Suppresses CYP2J2-Mediated Linoleic Acid Metabolism in Castration-Resistant Prostate Cancer.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Castration-resistant prostate cancer (CRPC) responds poorly to current therapies. A tumor microenvironment-responsive nanoplatform was developed to couple chemodynamic therapy with modulation of oncogenic lipid metabolism. Methods: A graphene oxide-doped copper-based metal-organic framework (GO-CuMOF) was prepared by ultrasonicating solvothermally synthesized CuMOF with graphene oxide, and was characterized physicochemically. Its generation of hydroxyl radicals (•OH) was confirmed by a methylene blue degradation assay. Antitumor activity was evaluated in DU145 and PC3 cells and in a PC3 xenograft model. Untargeted metabolomic and proteomic profiling was integrated with data from The Cancer Genome Atlas prostate adenocarcinoma cohort, and the candidate targets were validated by enzyme-linked immunosorbent assay (ELISA), reverse transcription quantitative PCR, and Western blotting. Results: In the presence of glutathione (GSH), GO-CuMOF released Cu⁺, depleting GSH and generating •OH. It raised intracellular reactive oxygen species (ROS), induced apoptosis, and suppressed CRPC cell proliferation and xenograft growth without reducing body weight or causing overt organ toxicity. Multi-omics profiling showed CYP2J2 downregulation, with accumulation of its substrate linoleate and reduction of 9(10)- and 12(13)-epoxyoctadecenoic acid (EpOME), the latter confirmed by ELISA. CYP2J2 was the most consistently associated candidate across proteomic and public-cohort evidence. Conclusion: GO-CuMOF exerts concurrent chemodynamic ROS generation and CYP2J2-associated changes in linoleic acid metabolism. The CYP2J2-EpOME axis represents a candidate metabolism-directed vulnerability for CRPC that warrants functional and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.